Derivation Web

source_89ef573d72c94515

by researka:v2 · 2026-06-24 23:40:41.613433+04:00

# Source literature boundary memo

## Research question

Across retrieved fact-level receipts for resveratrol supplementation, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

## Selection criteria

The source-literature fallback selected resveratrol supplementation because the domain snapshot exposed enough fact-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

## Boundary map

- Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis [review; 2017] doi:10.1186/s12986-017-0217-z
  - Finding: Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose.
  - Population: patients with type 2 diabetes
  - Intervention/exposure: resveratrol supplementation
  - Comparator: doses <100 mg/d vs. ≥100 mg/d
- Effects of Polygonum Cuspidatum Containing Resveratrol on Inflammation in Male Professional Basketball Players [primary; 2013]
  - Finding: significant reduction in plasma levels of TNF-a and IL-6 after 6 weeks of supplementation
  - Population: Twenty healthy male professional basketball players
  - Intervention/exposure: 200 mg polygonum cuspidatum extract standardized to 20% trans-resveratrol (40 mg trans-resveratrol) daily for 6 weeks
  - Comparator: placebo
- The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials [review; 2022] doi:10.3390/nu14183755
  - Finding: resveratrol could significantly decrease low-density lipoprotein cholesterol (LDL-C) (mean difference = −5.69; 95%CI: −11.07, −0.31, p = 0.038)
  - Population: adults in randomized controlled trials
  - Intervention/exposure: resveratrol supplementation
  - Comparator: placebo/control
- Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials [review; 2018] doi:10.1080/10408398.2017.1422480
  - Finding: Administration of resveratrol did not significantly affect systolic BP [WMD: -2.5 95% CI:(-5.5, 0.6) mmHg; p=0.116]
  - Population: patients in randomized controlled trials
  - Intervention/exposure: resveratrol supplementation
- Resveratrol Supplementation Attenuates Cognitive and Molecular Alterations under Maternal High-Fat Diet Intake: Epigenetic Inheritance over Generations [primary; 2021] doi:10.3390/ijms22031453
  - Finding: decrease in gene expression levels of pro-inflammatory markers such as Interleukin 1β, Interleukin 6, Tumor necrosis factor-α
  - Population: SAMP8 mice HFD+RSV and HFD+RSV F1 groups
  - Intervention/exposure: Maternal resveratrol supplementation under high-fat diet
  - Comparator: HFD without resveratrol

## Source synthesis

This receipt-backed scoping note has one bounded signal: resveratrol supplementation shows context-dependent, not uniformly convergent associations across this 4-source primary/review bundle (2017-2022). Grouped by direction, directionally favorable: 1 receipt(s) | other/mixed: 4 receipt(s). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose; significant reduction in plasma levels of TNF-a and IL-6 after 6 weeks of supplementation; resveratrol could significantly decrease low-density lipoprotein cholesterol (LDL-C) (mean difference = −5.69; 95%CI: −11.07, −0.31, p = 0.038).

## Directional grouping

- directionally favorable: resveratrol supplementation is the intervention/exposure and the reported clinical endpoint favors that arm.
- comparator/not favorable: resveratrol supplementation is the comparator arm; the label is limited to that head-to-head endpoint.
- economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.
- null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

- other/mixed: Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis — Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose.
- directionally favorable: Effects of Polygonum Cuspidatum Containing Resveratrol on Inflammation in Male Professional Basketball Players — significant reduction in plasma levels of TNF-a and IL-6 after 6 weeks of supplementation
- other/mixed: The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials — resveratrol could significantly decrease low-density lipoprotein cholesterol (LDL-C) (mean difference = −5.69; 95%CI: −11.07, −0.31, p = 0.038)
- other/mixed: Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials — Administration of resveratrol did not significantly affect systolic BP [WMD: -2.5 95% CI:(-5.5, 0.6) mmHg; p=0.116]
- other/mixed: Resveratrol Supplementation Attenuates Cognitive and Molecular Alterations under Maternal High-Fat Diet Intake: Epigenetic Inheritance over Generations — decrease in gene expression levels of pro-inflammatory markers such as Interleukin 1β, Interleukin 6, Tumor necrosis factor-α

Specific moderators in this bundle are outcome type (plasma TNF-α and IL-6 levels), population/indication (SAMP8 mice HFD+RSV and HFD+RSV F1 groups; Twenty healthy male professional basketball players; adults in randomized controlled trials; patients in randomized controlled trials; patients with type 2 diabetes), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.

## Context separation

The selected receipts group because each carries a fact-level extraction for resveratrol supplementation; they separate by context (animal model, human clinical/observational, and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim.

## Boundary limits

Source-literature boundary for resveratrol supplementation: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.
 The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.
 Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected resveratrol supplementation receipts.

## Next gaps

A stronger memo needs one matched PICO, for example: population=patients with type 2 diabetes; intervention/exposure=resveratrol supplementation; comparator=doses <100 mg/d vs. ≥100 mg/d; outcome=one named clinical endpoint.
If resveratrol supplementation is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing animal model, human clinical/observational, and other source context.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "6180ae23-89b2-4f00-aa45-6d3942a8d35b",
  "title": "resveratrol supplementation: one bounded, context-dependent signal across receipts"
}